跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack - TGA Drug Approval Details
Approvals
/
TGA
/
FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack
Approved
STANDARD
FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack
Novartis Pharmaceuticals Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
96b110a444aeb170
Company
Novartis Pharmaceuticals Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
96b110a444aeb170
Product Name
FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack
Artg Id
315450
Artg Name
FYNEFTA fingolimod (as hydrochloride) 0.25 mg capsule blister pack
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path
/organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date
2019-04-12
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
96b110a444aeb170
Type
Standard
Back to TGA Approvals
